Blennow M, Granström M, Jäätmaa E, Olin P
Department of Pediatrics, Karolinska Institute, Stockholm, Sweden.
Pediatrics. 1988 Sep;82(3):293-9.
The rate of adverse reactions and the immunogenicity of a two-component acellular pertussis vaccine as compared with a plain whole-cell vaccine and a placebo were evaluated for primary immunization in 319 6-month-old infants in a double-blind randomized clinical trial. The acellular vaccine produced few and mild systemic and local reactions. Fever (greater than or equal to 38 degrees C) occurred in 6% to 8% of acellular vaccinees as opposed to 25% to 37% of whole-cell vaccinees. Redness (greater than or equal to 1 cm) appeared in 2% to 13% of the acellular vaccine and 24% to 32% of the whole-cell vaccine recipients. Antibody response to pertussis toxin measured in a neutralization test was obtained in 97% to 100% of the infants receiving either two or three doses of the acellular vaccine as compared to 59% after three doses of whole-cell vaccine.
在一项双盲随机临床试验中，对319名6个月大婴儿进行初次免疫，评估了一种双组分无细胞百日咳疫苗与普通全细胞疫苗和安慰剂相比的不良反应发生率和免疫原性。无细胞疫苗产生的全身和局部反应少且轻微。6%至8%接种无细胞疫苗的婴儿出现发热（体温大于或等于38摄氏度），而接种全细胞疫苗的婴儿中这一比例为25%至37%。2%至13%接种无细胞疫苗的婴儿出现红肿（直径大于或等于1厘米），接种全细胞疫苗的婴儿中这一比例为24%至32%。在接受两剂或三剂无细胞疫苗的婴儿中，97%至100%在中和试验中对百日咳毒素产生抗体反应，而接种三剂全细胞疫苗后这一比例为59%。
